Gorov, Harry
Volume 28 · 28 F.T.C. 38
deceptive advertisinghealth claims
Cite this decision
Gorov, Harry, 28 F.T.C. 38 (1939). Consumer Law Library, https://consumerlawlibrary.org/decisions/v028-0005
Report an error in this record (decision id v028-0005)
Cited by 0 later FTC decisions
Cites
Text (OCR of the scan at left; may contain errors)
IN THE MA'ITER OF HARRY GOROV TRADING AS ISABELLA LABORATORIES, HARTMAN WHOLESALE DRUG CO., INC., ET AL.
COMPLAINT, FINDINGS, AND ORDER IN REGARD TO THE ALLEGED VIOLATION OF SEC. 15 l)F AN ACT OF CONGRESS APPROVED SEPT. 26, 1914 Docket 3609. Complaint, Sept. 28, 1938-Decision, Jan. 7, 1939 Where an individual, corporate wholesale drug concern, and eight retail drug companies located in Chicago, and engaged in sale and distribution, under trade name "281," of medical preparation for reducing, active ingredient in which was a powerful stimulator of body metabolism which resulted, through accelerated rate thereof, in the more rapid destruction of body tissues and particularly fat, and also in marked toxic effect, causing, in some cases, direct degenerative changes in the vital organs and formation of bilateral cataracts on the eyes of users- Caused to be disseminated false advertisements which contained, as typical, such representations as that said compound was recognized and widely prescribed by practicing physicians as aid in weight reduction, requiring no change in diet or normal mode of living or exet·cising, and that voluntary letters received during the past 4 years testified to the effect that no ill effects were experienced, and thereby disseminated, or caused to be disseminated, false advertisements in commerce which induced, or were likely to induce, purchase of aforesaid drug and were intended so to do; Facts being preparation in question was not widely prescribed as aforesaid, many ill effects were often experienced from use thereof, and such use, under conditions prescribed in said advertisements and under such condi· tions as w~re customary and usual, was injurious to the health of the users and caused loss or serious impairment of eyesight, and injured and Impaired otller functions of the body;
With effect of misleading substantial portion of purchasing public into errone· ous and mistaken belief that thelr said representations were true, and with result that public, acting under mistaken and erroneous belief induced by such false and misleading statl'ments and representations, purchased substantial volume of said preparation:
lleld, That such acts and practices were all to the prejudice of the public and constituted unfair and deceptive acts and practices in commerce. !J!r. Geraril A. Rault for the Commission. lValler & Neilow, of Chicago, Ill., for respondents, with the exception of Harry Gorov, who was represented by 11/r. Eugene Bernstein, of Chicago, Ill.
Complaint Pursuant to the provisions o£ the Federal Trade Commission Act, and by virtue o£ the authority vested in it by said act, the Federal Trade Commission having reason to believe that Harry Gorov, ·an jndividual trading as Isabella Laboratories, and Hartman Wholesale ISABELLA LABORATORIES ET AL, 39 38 Complaint Drug Co., Inc., Hartman '\Vabash Drug Co., Hartman Drug Co., Hartman North Shore Drug Co., Hartman Pharmacy, Inc., Hartman Medinah Drug Co., Hartman Lasalle Drug Co., Hartman Stony Island Drug Co., and Hartman Sheridan Drug Co., corporations~ hereinafter referred to as respondents, have violated the provisions of the said act, and it appearing to the Commission that a proceeding by it in respect thereof would be in the public interest, hereby issues its complaint stating its charges in that respect as follows: PARAGRAPH 1. Respondenl Harry Gorov is an individual trading and doing business under the name of Isabella Laboratories with his principal place of business located at 220 South State Streett Chicago, Ill.
Hartman 'Wholesale Drug Co., Inc., is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 59 East Van Buren Street, Chicago, Ill.
Hartman '\Vabash Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 401 South '\Vabash Avenue, Chicago, Ill. Hartman Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 338 South Clark Street, Chicago, Ill. Hartman North Shore Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 4600 Broadway, Chicago, Ill. Hartman Pharmacy, Inc., is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 2059 '\Vest Madison Street, Chicago, Ill. Hartman Medinah Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 507 North Michigan Avenue, Chicago, Ill. Hartman Lasalle Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 41 South Lasalle Street, Chicago, Ill. Hartman Stony Island Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 6701 Stony Island A venue, Chicago, Ill. Hartman Sheridan Drug Co. is a corporation created and existing under the laws of the "State of Illinois with its office and principal place of business located at 701 Sheridan Road, Chicago, Ill. PAR. 2. The individual respondent and corporate respondents, hereinabove named, have acted together and in cooperation with each other in carrying out the acts and practices herein alleged. 40 FEDERAL TRADE COJ.Hl\IISSION DECISIONS Complaint 28F. T. C.
PAR. 3. The individual respondent, Harry Gorov, trading and doing business as Isabella Laboratories, is engaged in distributing a medical preparation sold under the trade name of "281." Corporate respondent Hartman 'Vholesale Drug Co., Inc., is engaged in wholesaling drugs to the other corporate respondents named herein. Included among the drugs so sold to the other corporate respondents is the preparation known as "281." All o:f said other corporate respondents are engaged in the retail drug business and sell among other drugs the preparation known as "281." PAR. 4. In the course and conduct o:f their said businesses, and for the purpose o:f inducing the purchase o:f the preparation known as "281," respondents have caused false advertisements containing representations as to the safety with which said medicine product "281" may be used to be disseminated by means of the United States mails, by means of circulars and other advertising material distributed between and among the various States o:f the United States, and by means o:f advertisements inserted in newspapers and other publications distributed and circulated between and among the various States of the United States and in the District of Columbia. Among and typical of the representations contained in said false advertisements· so used and disseminated as aforesaid are the following: A Sll\IPLE METHOD FOR REDUCING WEIGHT "2 8 1"
"281" is a compound recognized and widely prescribed by practicing physicians as aids In weight reduction. No change In diet or the normal mode of living or exercising Is necessary. Voluntary letters received during the past 4 years testify to the fact that no ill eflects are experienced. The representations contained in the advertisement hereinabove set out, and in other advertisements similar thereto but not set out herein, are false, misleading, and untrue. This preparation is not widely prescribed by practicing physicians, as an aid in reducing weight. Many ill effects are often experienced from its use. Said advertisements of responder1ts are also false in that they fail to reveal that the use of this product under the conditions prescribed in. said advertisements, and under such conditions as are customary and usual, may be injurious to the health of the user thereof by causing loss or serious impairment of eyesight and in other ways injuring or impairing the functions of the human body. The true facts are that the active agent contained in said preparation "281" is the drug dinitrocresol. This drug is a powerful stimulator of body metabolism. Through the accelerated metabolism rate ISABELLA LABORATORIES ET AL. 41 38 Findings caused by the use of this drug body tissues, particularly fat, are more rapidly destroyed. This drug, however, has a marked toxic effect, causing, in some cases, direct degenerative changes in the vital organs and the formation of bilateral cataracts on the eyes of the persons subjected to its use.
PAR. 5. The aforesaid false advertisements disseminated in com-· merce in the manner above <.lescribed induce, or are likely to induce, directly or indirectly, the purchase of a drug, to wit: the preparation known as "281."
PAR. 6. The use by the respondents of the foregoing false, deceptive, and misleading statements and representations with respect to the product "281" disseminated as aforesaid has had and now has the capacity and tendency to and does mislead and deceive a substantial portion of the purchasing public into the erroneous and mistaken belief that such statements and representations are true and into the purchase of respondent's said medical preparation as a result of such erroneous and mistaken beliefs. PAn. 7. The aforesaid acts and practices of respondent as herein alleged are all to the prejudice and injury of the public and constitute unfair and deceptive acts and practices in commerce within the intent and meaning of the Federa~ Trade Commission Act. REPORT, FINDINGS AS TO 'lhe FACTS, AND ORDER Pursuant to the provisions of the Federal Trade Commission Act, the Federal Trade Commission, on September 28, 1938, issued and served its complaint in this proceeding upon respondents charging them with the use of unfair and deceptive acts and practices in commerce in violation of the provisions of said act. On October 19, 1938, respondent Harry Gorov, trading as Isabella Laboratories, filed his answer, in which answer he admitted all the material allegations of fact set forth in said complaint and waived all intervening procedure and further hearing as to said facts. On November 18, 1938, all of the other respondents named herein filed their answer, in which answer they also ndmitted all the material allegations of fact set forth in said complaint and waived all intervening procedure and further hearing as to said facts. Thereafter, the proceeding regularly came on for final hearing before the Commission on the said complaint and the answer thereto, and the Commission, having duly considered the matter, and being now fully advised in the premises, finds that this proceeding is in the interest of the public, and makes this its findings as to the facts and its conclusion drawn therefrom. Findings 28 F. T. C. FINDINGS AS TO THE FACTS PARAGRAPH 1. The respondent Harry Gorov is an individual trading and doing business under the name of Isabella Laboratories with his principal place of business located at 220 South State Street, Chicago, Ill. Respondent Hartman "Wholesale Drug Co., Inc., is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 59 East Van Buren Street, Chicago, Ill. Respondent Hartman Wabash Drug Co. is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 401 South 'Vabash A venue, Chicago, Ill. Respondent Hartman Drug Co. is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 338 South Clark Street, Chicago, Ill. Respondent Hartman North. Shore Drug Co. is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 46'00 Broadway, Chicago, Ill. Respondent Hartman Pharmacy, Inc., is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 2059 'Vest Madison Street, Chicago, Ill. Respondent Hartman Medinah Drug Co. is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 507 North Michigan A venue, Chicago, Ill. Respondent Hartman Lasalle Drug Co. is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 41 South Lasalle Street, Chicago, Ill. Respondent Hartman Stony Island Drug Co. is a corporation created and existing under the laws of the State of Illinois with its office and principal place of business located at 6701 Stony Island A venue, Chicago, Ill. Respondent Hartman Sheridan Drug Co. is a corporation created and existing under the laws of the State of Illinois, with its office and principal place of business located at 701 Sheridan Road, Chicago, Ill.
PAR. 2. The individual respondent and corporate respondents, named in paragraph 1, have acted together and in cooperation with each other in carrying out the acts and practices herein found. PAR. 3. The individual respondent, Harry Gorov, trading and doing business as Isabella Laboratories, is engaged in distributing a medical preparation sold under the trade name of "281." Corporate respondent Hartman 'Vholesale Drug Co., Inc., is engaged in wholesaling drugs to the other corporate respondents named herein.
ISABELLA LABORATORIES ET AL. 43 38 Findings Included among the drugs so sold to the other corporate respondents is the preparation known as "281." All of said other corporate respondents are engaged in the retail drug business and sell among other drugs the preparation known as "281."
PAR. 4. For the purpose of inducing the purchase of the preparation known as "281," all respondents have caused false advertisements containing representations as to the safety with which said medicinal product "281" may be used to be disseminated by means of the United States mails, by means of circulars and other advertising material distributed between and among the various States of the United States, and by means of advertisements inserted in newspapers and other publications distributed and circulated between and among the various States of the United States and in the. District of Columbia.
Among and typical of the representations contained in said false advertisements so used and disseminated as aforesaid are the following :
A Sin PLE METHOD FOR REDUCING WEIGHT "281"
"281" is a compound t·ecoguized and widely prescribed by practicing physicians as aids in weight reduction. No change in diet or the normal mode of livln~ or exercising is necessary. Voluntary letters received during the past 4 years testify to the fact that no ill effects are experienced. The Commission finds that the representations contained in the advertisement hereinabove set out, and in other advertisements similar thereto but not set out herein, are false, misleading, and untrue. In truth and in fact the preparation designated "281" is not widely prescribed by practicing physicians as an aid in reducing weight. The Commission finds that many ill effects are often experienced from its use. The Commission further finds that the use of said product under the conditions prescribed in said advertisements, and under such conditions as are customary and usual, is injurious to the health of the users thereof. Use of the product causes loss or serious impairment of eyesight. Use of the product also injures and impairs other functions of the human body.
The Commission finds that the active agent contained in said preparation "281" is the drug dinitrocresol, which drug is a powerful stimulator of body metabolism. Through the accelerated metabolism rate caused by the use of this drug body tissues, particularly fat, are more rapidly destroyed. This drug, however, has a marked toxic effect. causing, in some cases, direct degenerative changes in the vital 200346m--40--vol.28----6 Order 28 F. T. C. organs and the formation of bilateral cataracts on the eyes of the persons subjected to its use.
PAR. 5. The aforesaid false advertisements disseminated in commerce in the manner above described induce, or are likely to induce, directly or indirectly, the purchase of a drug, to wit: the preparation known as "281."
PAR. 6. Each and all of the false and misleading statements and representations made by respondents in their advertising in newspapers and other publications and by means of circulars and other advertising material, in offering for sale and selling the product "281," had, and now has, the capacity and tendency to, and does, mislead a substantial portion of the purchasing public into the erroneous and mistaken belief that such representations are true. Acting under the mistaken and erroneous beliefs induced by the false and misleading statements and representations, hen•in above found, the public has purchased a substantial volume of the medicinal preparation designated "281.'' CONCLUSION The above acts and practices of the respondents as herein found are all to the prejudice of the public and constitute unfair and deceptive acts and practices in commerce within the intent and meaning of the Federal Trade Commission Act.
ORDER TO CEASE AND DESIST This proceeding having been heard by the Federal Trade Commission upon the complaint of the Commission and the answers of respondents in which answers respondents admit all the material allegations of fact set forth in said complaint and state that they waive all intervening procedure and further hearing as to said facts and the Commission having made its findings as to the facts and conclusion that said respondents have violated the provisions of the Federal Trade Commission Act.
It i-9 ordered, That the re:::pondent Harry Gorov, trading as Isabella Laboratories, or under any other trade name, and respondents Hartman wholesale Drug Co., Inc., Hartman 'Vabash Drug Co., Hartman Drug Co., Hartman North Shore Drug Co., Hartman Pharmacy, Inc., Hartman Medinah Drug Co., Hartman Lasalle Drug Co., Hartman Stony Island Drug Co., and Hartman Sheridan Drug Co., their officers and their respective representatives, agents, and employees do forthwith cease and desist from: Disseminating or causing to be disseminated any advertisement by means of the United States mails or in commerce by any means for ISABELLA LABORATORIES ET AL. 45 38 Order the purpose of inducing or which is likely to induce directly or indirectly the purchase of the drug known as "281" whether sold under .the same name or under any other trade name, or disseminating or causing to be disseminated any advertisement by any means for the purpose of inducing or which is likely to induce directly or indirectly the purchase in commerce of said preparation "281" which advertisements represent that the preparation "281" is prescribed by practicing physicians as an aid in reducing weight and that no ill effects are experienced from its use, and which advertisements fail to state 'that the use of this preparation under the conditions prescribed in said advertisements or under such conditions as are customary and usual may be injurious to the health of the user thereof. by causing loss or serious impairment of eyesight and in other ways injuring and impairing the functions of the human body. It i8 further ordered, That respondents shall within 10 days after service upon them of this order file with the Commission an interim report in writing stating whether they intend to comply with this order and if so, setting forth in detail the manner and form in which they intend to comply; and that within 60 days after service upon them of this order said respondents shall file with the Commission a report in writing setting forth in detail the manner and f()rm in which they have complied with this order.
Syllabus 28F.T. C.